Pfizer records high earnings despite problems with antismoking drug

NEW YORK Pfizer released its second earnings report and despite the loss of more than a third of its sales for its anti-smoking drug Chantix due to safety concerns, the company reported that earnings more than doubled on higher sales of its prescription drugs, according to published reports.

The company earned $2.78 billion in the second quarter, compared to $1.27 billion a year earlier, when Pfizer took large charges for restructuring and merger-related costs.

Company revenue rose 9 percent to $12.13 billion, but would have increased only 2 percent if not for the weak dollar, which boosts the value of overseas sales when converted back into U.S. currency.

Pfizer’s U.S. sales fell 2 percent, hurt by decreasing demand for Chantix, a new medicine that Pfizer has been counting on to drive earnings growth in coming years, and loss of patent protection on allergy drug Zyrtec and cancer drug Camptosar.

Login or Register to post a comment.